Skip to main content

Nemaura Medical announces expansion of SugarBEAT® offering  with BEAT® Diabetes digital subscription services

Written by Customer Service on . Posted in Public Companies.

Loughborough, England, Dec. 05, 2019 (GLOBE NEWSWIRE) —  Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for diabetics and pre-diabetics, announced that it has expanded its SugarBEAT® CGM capabilities by launching a new digital health offering, BEAT® Diabetes (www.BEATdiabetes.life), which focuses on the prevention and reversal of Type II diabetes through a range of holistic app and coaching services encouraging behavioural change. Both BEAT® Diabetes and SugarBEAT® target the underserved $69 billion market for Type 2 diabetics and $50 billion market for pre-diabetics.   
Combining apps and coaching for patients has been independently and clinically proven to enhance the impact of diabetes management. The full range of services within the BEAT® Diabetes offering, which will be available under a variety of subscription packages, will include an app to track and provide personal lifestyle recommendations to patients according to their blood glucose levels, one-on-one coaching, and routine measurement of other parameters that allow improved disease management through early monitoring. BEAT® Diabetes will track the user’s blood glucose trends and provide information about how their condition is being affected by individual lifestyle factors. SugarBEAT® is a non-invasive daily-use CGM device, with CE mark approval in Europe, which sits on top of the skin and transmits glucose readings at five minute intervals to a phone app . The flexibility afforded by a daily use wear time allows users to selectively utilize SugarBEAT® on days they prefer. This compares to conventional CGM technologies that require penetration of the skin and extended continuous day usage for periods between 10-14 days, which significantly limits the potential user population.By combining glucose readings and daily glucose trend data provided by SugarBEAT® with digital coaching and support services provided by BEAT® Diabetes, users will be better able to achieve lifestyle changes to potentially prevent or reverse type II diabetes. Additionally, insulin users who do not currently use any CGMs have a non-invasive flexible CGM alternative, which can empower them with glucose profile data on days of their choosing, to improve management of their glucose fluctuations and allow insulin dose adjustment using confirmatory finger stick readings.Dr. Faz Chowdhury, CEO of Nemaura, commented, “Diabetes is a global pandemic affecting over 450 million people worldwide. This disease has a major impact not only on individuals, but also employers, healthcare providers and insurers that incur substantial long-term costs to help patients manage their condition. We believe that simple monitoring of glucose is not enough. Patients need access to a variety of methods to better manage their glucose. The combination of our self-monitoring wearable platform with digital support and prompts, as well as one-on-one coaching through the BEAT® Diabetes app is designed to provide greater optionality and flexibility to both patients and payors alike.”The launch of the BEAT® Diabetes website is intended to allow both individuals and corporate users to register their early interest so that Nemaura can provide them with details of the various subscription packages that will be available. The holistic diabetes management service is also intended to augment sales of SugarBEAT® by its licensees. For more information on the direct-to-consumer and corporate subscription offerings click here, www.BEATdiabetes.lifeAbout SugarBEAT®SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes throughout the day. SugarBEAT® is expected to help a person with diabetes and pre-diabetes better track how lifestyle factors can impact daily glucose level trends (known as an Ambulatory Glucose Profile) thereby significantly improving the amount of daily time spent in range. For more information, visit www.SugarBEAT.com.Nemaura received CE Mark approval for SugarBEAT® as a Class IIb medical device in May 2019. Subsequent to the approval, the Company commenced the first phase of the product launch and has gathered feedback from diabetic and non-diabetic users, enabling fine tuning of the user experience. These findings were reported during a symposia held by the company at the European Association for the Study of Diabetes, held in Barcelona in September 2019, and are available for viewing on the Company’s website (https://nemauramedical.com/easd-symposia-2019).About Nemaura Medical, Inc.:Nemaura Medical, Inc. (NMRD), is a medical technology company commercializing SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and pre-diabetics better manage their glucose levels by spending more time in range.  Insulin users can adjunctively use SugarBEAT® when calibrated by a finger stick reading.For more information visit: www.NemauraMedical.com.Cautionary Statement Regarding Forward-Looking Statements:The statements in this press release that are not historical facts, and may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Nemaura’s ongoing studies, including the safety and efficacy of Nemaura’s SugarBEAT® system, the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell SugarBEAT®, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to SugarBEAT®. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.Contact:
Crescendo Communications, LLC
212-671-1021
NMRD@crescendo-ir.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.